vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
15.33
+1.30 (9.27%)
Aug 14, 2025, 11:16 AM - Market open
vTv Therapeutics Revenue
vTv Therapeutics had revenue of $17.00K in the twelve months ending June 30, 2025, down -98.30% year-over-year. In the year 2024, vTv Therapeutics had annual revenue of $1.02M.
Revenue (ttm)
$17.00K
Revenue Growth
-98.30%
P/S Ratio
6,237.90
Revenue / Employee
$739
Employees
23
Market Cap
109.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.02M | -1.99M | -49.61% |
| Dec 31, 2021 | 4.01M | -2.41M | -37.56% |
| Dec 31, 2020 | 6.41M | 3.65M | 132.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VTVT News
- 1 day ago - vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 days ago - vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - GlobeNewsWire
- 7 days ago - vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - GlobeNewsWire
- 2 months ago - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
- 3 months ago - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire